Literature DB >> 21253743

[Monitoring treatment with biologics in non-infectious uveitis].

T Barisani-Asenbauer1.   

Abstract

Biologics are increasingly being used in the treatment of non-infectious sight-threatening uveitis. While the advantages of biologics, such as avoidance of glucocorticoid side-effects or rapid control of intraocular inflammation therapy refractive to corticosteroids, cannot be dismissed the treating ophthalmologist should be aware of the specific risks. Biologics increase the risk for severe and atypical infections, lymphomas and other malignancies. Treatment should only be initiated when profound knowledge about indications, management and monitoring of treatment with biologics is readily available. Weighing up the risks versus the benefits should be made on an individual basis and guide patient consultation.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21253743     DOI: 10.1007/s00347-010-2257-x

Source DB:  PubMed          Journal:  Ophthalmologe        ISSN: 0941-293X            Impact factor:   1.059


  28 in total

1.  The dream of biologics in uveitis.

Authors:  Annabelle A Okada
Journal:  Arch Ophthalmol       Date:  2010-05

2.  [Intraocular inflammations. A diagnostic and therapeutic challenge].

Authors:  U Pleyer
Journal:  Ophthalmologe       Date:  2005-04       Impact factor: 1.059

3.  Distress, depression and coping in HLA-B27-associated anterior uveitis with focus on gender differences.

Authors:  S M Maca; A W Schiesser; A Sobala; K Gruber; G Pakesch; C Prause; T Barisani-Asenbauer
Journal:  Br J Ophthalmol       Date:  2010-10-22       Impact factor: 4.638

4.  Risk of malignancy among patients with rheumatic conditions.

Authors:  E Thomas; D H Brewster; R J Black; G J Macfarlane
Journal:  Int J Cancer       Date:  2000-11-01       Impact factor: 7.396

5.  Relationship between serum infliximab levels and acute uveitis attacks in patients with Behcet disease.

Authors:  Sunao Sugita; Yukiko Yamada; Manabu Mochizuki
Journal:  Br J Ophthalmol       Date:  2010-06-27       Impact factor: 4.638

Review 6.  Laser flare-cell photometry: methodology and clinical applications.

Authors:  John G Ladas; Noel C Wheeler; Patrick J Morhun; Steven O Rimmer; Gary N Holland
Journal:  Surv Ophthalmol       Date:  2005 Jan-Feb       Impact factor: 6.048

Review 7.  Biologics - beyond the joints.

Authors:  Zoltán Szekanecz; Sándor Szántó; Zoltán Szabó; Andrea Váncsa; Szilvia Szamosi; Nóra Bodnár; Gabriella Szücs
Journal:  Autoimmun Rev       Date:  2010-08-10       Impact factor: 9.754

8.  Interobserver agreement in grading activity and site of inflammation in eyes of patients with uveitis.

Authors:  John H Kempen; Sudha K Ganesh; Virender S Sangwan; Sivakumar R Rathinam
Journal:  Am J Ophthalmol       Date:  2008-08-08       Impact factor: 5.258

Review 9.  Comparative overview of safety of the biologics in rheumatoid arthritis.

Authors:  Majed Khraishi
Journal:  J Rheumatol Suppl       Date:  2009-06

Review 10.  Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop.

Authors:  Douglas A Jabs; Robert B Nussenblatt; James T Rosenbaum
Journal:  Am J Ophthalmol       Date:  2005-09       Impact factor: 5.258

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.